Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NEO

NeoGenomics, Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for NEO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

NeoGenomics, Inc. (NASDAQ: NEO) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 06:14 UTC.

What NeoGenomics, Inc. does

NeoGenomics is a cancer-focused diagnostics company that operates accredited laboratories in the United States and the United Kingdom, providing oncology diagnostic testing and consultative services. The company offers a comprehensive range of testing methods including cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular residual disease testing, molecular testing, and morphologic analysis. Services are provided to community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical companies.

Summarized from NeoGenomics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-12.91%
Debt/equity0.41

Revenue, margins & earnings

FY2021: net loss $8M on revenue $484M$484MFY2021FY2022: net loss $144M on revenue $510M$510MFY2022FY2023: net loss $88M on revenue $592M$592MFY2023FY2024: net loss $79M on revenue $661M$661MFY2024FY2025: net loss $108M on revenue $727M$727MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-05
  • 2026-10-05Pres & Chief Operating OfficerOption exercise17,562—
  • 2026-10-05Pres & Chief Operating OfficerTax withholding-6,911—
  • 2026-10-05Pres & Chief Operating OfficerRestricted Stock UnitOption exercise-17,562—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does NeoGenomics, Inc. do?

NeoGenomics is a cancer-focused diagnostics company that operates accredited laboratories in the United States and the United Kingdom, providing oncology diagnostic testing and consultative services.

When did NEO last file with the SEC?

NeoGenomics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:14 UTC. This page is also available as JSON at /api/data?ticker=NEO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NEO and 5,000+ tickers.

Create a free account — keep NEO
For your agent
GET /api/data?ticker=NEO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt